PCM
LXRX icon

Price Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Price Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-134,529
Closed -$1.35M – 110
2018
Q2 		$1.35M Buy
+134,529
New +$1.38M 0.67% 3

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SGA
Sector Gamma AS Oslo, Norway $423M AUM 17.56% 1-Year Est. Return

Price Capital Management's LXRX Position: Q3 2018 in Review

Price Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2018, closing a stake of 134,529 shares — an estimated $1.35M sold.

Price Capital Management first reported a position in LXRX in Q2 2018 and held it in 1 quarter. The position peaked at $1.35M in Q2 2018. 119 funds tracked by Wall St. Rank hold LXRX as of Q3 2018.

  • Price Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Price Capital Management sold 134,529 Lexicon Pharmaceuticals shares in Q3 2018, an estimated $1.35M.
  • Price Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Price Capital Management's Lexicon Pharmaceuticals position peaked at $1.35M in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2018.

Based on Price Capital Management's 13F filing for Q3 2018, filed 29 Oct 2018.